• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SPRO

    Spero Therapeutics Inc.

    Subscribe to $SPRO
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company is headquartered in Cambridge, Massachusetts.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: sperotherapeutics.com

    Peers

    $CFRX
    $DBVT
    $KMPH

    Recent Analyst Ratings for Spero Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    12/20/2024$5.00Outperform → In-line
    Evercore ISI
    9/23/2022$2.00 → $8.00In-line → Outperform
    Evercore ISI
    10/1/2021Outperform → Perform
    Oppenheimer
    See more ratings

    Spero Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Rajavelu Esther was granted 185,000 shares, increasing direct ownership by 26% to 909,720 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      5/6/25 8:01:37 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Keutzer Timothy was granted 266,139 shares and sold $44,099 worth of shares (56,537 units at $0.78), increasing direct ownership by 39% to 741,439 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      2/5/25 9:04:51 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO & CBO Rajavelu Esther sold $16,137 worth of shares (20,689 units at $0.78) and was granted 366,139 shares, increasing direct ownership by 91% to 724,720 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      2/5/25 8:52:39 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & President Shukla Sath was granted 751,407 shares and sold $121,160 worth of shares (155,333 units at $0.78), increasing direct ownership by 52% to 1,736,883 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      2/5/25 8:31:31 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mahadevia Ankit sold $53,991 worth of shares (69,219 units at $0.78), decreasing direct ownership by 9% to 689,866 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      2/5/25 8:30:24 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO & CBO Rajavelu Esther sold $53,008 worth of shares (40,596 units at $1.31), decreasing direct ownership by 10% to 379,270 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      11/12/24 4:05:10 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mahadevia Ankit sold $7,981 worth of shares (5,912 units at $1.35), decreasing direct ownership by 0.77% to 759,085 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      8/29/24 6:43:37 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Keutzer Timothy sold $2,988 worth of shares (2,213 units at $1.35), decreasing direct ownership by 0.41% to 531,837 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      8/29/24 6:42:43 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & President Shukla Sath sold $3,722 worth of shares (2,757 units at $1.35), decreasing direct ownership by 0.24% to 1,140,809 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      8/29/24 6:36:07 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Shukla Sath sold $42,646 worth of shares (32,441 units at $1.31), decreasing direct ownership by 3% to 1,143,566 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      8/6/24 7:56:12 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Spero Therapeutics Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by Spero Therapeutics Inc.

      DEFA14A - Spero Therapeutics, Inc. (0001701108) (Filer)

      4/28/25 4:29:35 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Spero Therapeutics Inc.

      DEF 14A - Spero Therapeutics, Inc. (0001701108) (Filer)

      4/28/25 4:15:59 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Spero Therapeutics Inc.

      8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      4/28/25 4:02:27 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Spero Therapeutics Inc.

      SCHEDULE 13D/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      3/28/25 4:30:58 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      3/27/25 5:19:47 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Spero Therapeutics Inc.

      10-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      3/27/25 4:30:13 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Spero Therapeutics Inc.

      8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      2/28/25 5:11:12 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Regulation FD Disclosure

      8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      1/10/25 7:00:51 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      11/14/24 4:05:56 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Spero Therapeutics Inc.

      10-Q - Spero Therapeutics, Inc. (0001701108) (Filer)

      11/14/24 4:02:40 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Spero Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

      5/5/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

      4/28/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

      Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprioritization of the Company's pipeline in Q1 2025 Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into

      3/27/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

      CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.   To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this li

      3/18/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

      CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows: TD Cowen 45th Annual Health Care ConferenceCompany presentation:Tuesday March 4, 2025 Time:3:10 PM ET    To request a meeting or for

      2/25/25 10:15:22 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

      CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows: TD Cowen 45th Annual Health Care ConferenceCompany presentation: Wednesday March 5, 2025Time: 3:10 PM ET    To request a meeting or

      2/25/25 7:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

      Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022 Phase 3 PIVOT-PO Trial of Tebipenem HBr Reaches Over 60% Enrollment as of December 31, 2024; Remains on Track to Complete Enrollment in 2H 2025 Cash Balance and Cash Runway Guidance Remains into mid-2026 CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel tr

      1/10/25 7:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

      Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. "Enrollment in the Phase 3 tebipenem HBr trial is progressing well, and we are on track to complete enrollment in the

      11/14/24 4:05:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

      CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments fo

      11/7/24 4:05:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

      Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16 patients Phase 3 PIVOT-PO trial of tebipenem HBr remains on track for enrollment completion in 2H 2025 Cash runway extended into mid-2026 following a reduction in workforce and restructuring of operations; Unaudited Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (

      10/29/24 4:05:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Spero Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Spero Therapeutics downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Spero Therapeutics from Outperform to In-line and set a new price target of $5.00

      12/20/24 7:51:16 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Spero Therapeutics from In-line to Outperform and set a new price target of $8.00 from $2.00 previously

      9/23/22 7:52:34 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Spero Therapeutics from Outperform to Perform

      10/1/21 6:10:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Spero Therapeutics

      HC Wainwright & Co. reiterated coverage of Spero Therapeutics with a rating of Buy and set a new price target of $40 from $33 previously

      1/22/21 6:21:56 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Spero Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spero Therapeutics Inc.

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      11/14/24 5:37:55 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Spero Therapeutics Inc.

      SC 13G - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/24 4:25:21 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/23 11:47:54 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/23 11:16:34 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Spero Therapeutics Inc. (Amendment)

      SC 13D/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      1/20/23 4:08:03 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Spero Therapeutics Inc. (Amendment)

      SC 13D/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      11/14/22 5:02:41 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      10/3/22 4:40:46 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Spero Therapeutics Inc.

      SC 13G - Spero Therapeutics, Inc. (0001701108) (Subject)

      7/8/22 4:57:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/22 3:54:48 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/22 1:27:22 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Spero Therapeutics Inc. Financials

    Live finance-specific insights

    See more

    Spero Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

      5/5/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

      Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprioritization of the Company's pipeline in Q1 2025 Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into

      3/27/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

      CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.   To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this li

      3/18/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

      CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments fo

      11/7/24 4:05:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

      Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024New SPR720 in-vitro resistance data to be presented at IDWeek 2024 conference in OctoberCompany announces departure of Chief Medical Officer Kamal Hamed, MD, MPH, MBA; Appoints Board member and Chair of Development Committee John C. Pottage, Jr., M.D., as Special Advisor to oversee medical function; search ongoing for a new CMOCash balance of $63.5 million as of June 30, 2024; reiterate expected cash runway into late 2025Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Aug. 05, 2024 (GLO

      8/5/24 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

      CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline. To access the call, please dial 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and refer to conference ID 13747505, or click on this link and request a return call. The audio w

      7/29/24 4:05:16 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

      CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference call, and anticipates resuming quarterly earnings calls at the time it announces second quarter 2024 results. About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is

      5/8/24 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

      On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Initiated enrollment in PIVOT-PO, a pivotal Phase 3 clinical trial of oral Tebipenem HBr in cUTI Submitted IND for SPR206 and received FDA clearance to proceed with Phase 2 clinical trialReiterate expected cash runway into late 2025Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR)

      3/13/24 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

      CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13744458, or click on this Link and request a

      3/6/24 8:05:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

      Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. "Having made substantial progress across our late-stage pr

      11/13/23 4:05:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

      4/28/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

      CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer. Ms. Rajavelu will succeed Stephen DiPalma, who has served as the company's Interim CFO since August 1, 2023. "We are thrilled to welcome Esther to the executive leadership team as our new CFO and CBO. Esther brings a proven track record in corporate finance, from both indus

      11/1/23 8:05:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

      BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

      9/12/23 8:00:00 AM ET
      $PTCT
      $SPRO
      $TCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

      Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023 Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat "Sath" Shukla, Spero's current Chief Financial Officer and Treas

      6/14/23 8:05:00 AM ET
      $GSK
      $PFE
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

      CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO). "Kamal joins Spero with an impressive track record of building and leading successful anti-infective franchises," said Ankit Mahadevia, MD, Chief Executive Officer of Spero Therapeutics. "This, together with his unique blend of experience within the biotech industry, at global pharmaceutical companies, and as an infectious disease physician, make him the ideal candidate to join Spero as CMO. I am thrilled to have Kamal on our management team and look forward to working together."    Dr. Hamed has over 20

      9/15/22 4:05:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors

      CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Kathleen Tregoning to its Board of Directors. Currently the Chief Corporate Affairs Officer at Cerevel Therapeutics, Ms. Tregoning has more than two decades of experience in biotechnology and public policy. She succeeds outgoing Director Jean-François Formela, M.D., who has stepped down from Spero's Board as part of a planned transition, effective upon

      10/12/21 8:05:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer

      CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021. “Sath is an ideal fit for our management team given his experience leading financial strategy and executing within both clinical and commercial stage companies,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “He has extensive st

      12/17/20 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care